These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 15065093)

  • 21. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
    Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urine antibody against human cancer antigen NY-ESO-1.
    Jäger D; Stockert E; Karbach J; Herrlinger K; Atmaca A; Arand M; Chen YT; Gnjatic S; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2002 Aug; 2():10. PubMed ID: 12747755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer.
    Nakada T; Noguchi Y; Satoh S; Ono T; Saika T; Kurashige T; Gnjatic S; Ritter G; Chen YT; Stockert E; Nasu Y; Tsushima T; Kumon H; Old LJ; Nakayama E
    Cancer Immun; 2003 Jul; 3():10. PubMed ID: 12889868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
    Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432.
    Aoki M; Ueda S; Nishikawa H; Kitano S; Hirayama M; Ikeda H; Toyoda H; Tanaka K; Kanai M; Takabayashi A; Imai H; Shiraishi T; Sato E; Wada H; Nakayama E; Takei Y; Katayama N; Shiku H; Kageyama S
    Vaccine; 2009 Nov; 27(49):6854-61. PubMed ID: 19761832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
    Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C
    Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues.
    Wang XY; Chen HS; Luo S; Zhang HH; Fei R; Cai J
    Oncol Rep; 2009 Mar; 21(3):713-9. PubMed ID: 19212631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.
    Kawada J; Wada H; Isobe M; Gnjatic S; Nishikawa H; Jungbluth AA; Okazaki N; Uenaka A; Nakamura Y; Fujiwara S; Mizuno N; Saika T; Ritter E; Yamasaki M; Miyata H; Ritter G; Murphy R; Venhaus R; Pan L; Old LJ; Doki Y; Nakayama E
    Int J Cancer; 2012 Feb; 130(3):584-92. PubMed ID: 21413013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis.
    Mischo A; Bubel N; Cebon JS; Samaras P; Petrausch U; Stenner-Liewen F; Schaefer NG; Kubuschok B; Renner C; Wadle A
    Int J Oncol; 2011 Jul; 39(1):287-94. PubMed ID: 21573493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NY-ESO-1 may be a potential target for lung cancer immunotherapy.
    Lee L; Wang RF; Wang X; Mixon A; Johnson BE; Rosenberg SA; Schrump DS
    Cancer J Sci Am; 1999; 5(1):20-5. PubMed ID: 10188057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma.
    Lu Y; Wu LQ; Lü ZH; Wang XJ; Yang JY
    Chin Med J (Engl); 2007 Jun; 120(12):1042-6. PubMed ID: 17637219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [NY-ESO-1 and cancer immunotherapy].
    Peng JR; Leng XS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomic analysis of human sarcoma.
    Lee SY; Obata Y; Yoshida M; Stockert E; Williamson B; Jungbluth AA; Chen YT; Old LJ; Scanlan MJ
    Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2651-6. PubMed ID: 12601173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer.
    Qian F; Gnjatic S; Jäger E; Santiago D; Jungbluth A; Grande C; Schneider S; Keitz B; Driscoll D; Ritter G; Lele S; Sood A; Old LJ; Odunsi K
    Cancer Immun; 2004 Nov; 4():12. PubMed ID: 15521719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Expression of NY-ESO-1/LAGE-1 genes in hepatocellular carcinoma and autologous humoral responses induced thereby].
    Xing BC; Yuan YH; Hu ZG; Liu YX; Han Y; Liu N; Chen WF; Wang Y
    Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(23):1980-2. PubMed ID: 15730810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development.
    Gjerstorff MF; Kock K; Nielsen O; Ditzel HJ
    Hum Reprod; 2007 Apr; 22(4):953-60. PubMed ID: 17208940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
    Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ
    Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
    Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
    PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NY-ESO-1: review of an immunogenic tumor antigen.
    Gnjatic S; Nishikawa H; Jungbluth AA; Güre AO; Ritter G; Jäger E; Knuth A; Chen YT; Old LJ
    Adv Cancer Res; 2006; 95():1-30. PubMed ID: 16860654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.